COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effects of Clobazam on Sleep and Daytime Function in Patients With Epilepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02911025
Recruitment Status : Completed
First Posted : September 22, 2016
Last Update Posted : January 23, 2020
Information provided by (Responsible Party):
Pavlova, Milena,M.D., Brigham and Women's Hospital

Brief Summary:
The purpose of this study is to monitor the effect of Clobazam on sleep and daytime alertness in people with Epilepsy.

Condition or disease

Detailed Description:

Many studies show that patients with epilepsy frequently have disrupted sleep, as well as a high level of daytime sleepiness. This may be due to a sleep disorder, nighttime seizures that lead to disrupted sleep, and other abnormalities. Sleep complaints are widely reported among patients with various epilepsy syndromes.

Anti-seizure treatments may affect sleep. Effects vary by type of medication and other health issues. Generally, with improvement of seizure control, the sleep cycle improves and becomes more regular. However, some anti-seizure medications have been associated with insomnia. There have been studies that looked at sleep in relation to some anti-seizure medications. However, there are no currently available published reports on the effect of Clobazam (Onfi) on sleep.

Layout table for study information
Study Type : Observational
Actual Enrollment : 13 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Effects of Clobazam on Sleep and Daytime Function in Patients With Epilepsy
Study Start Date : January 2015
Actual Primary Completion Date : December 2017
Actual Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy
Drug Information available for: Clobazam

Patients Treated With Clobazam
Single group, patients treated with clobazam by their treating physician (no interventions from PI), followed longitudinally for 1 week after reaching effective clobazam dose.

Primary Outcome Measures :
  1. Change in sleep (total sleep time, wake after sleep onset) in patients with epilepsy treated with clobazam [ Time Frame: 1 week after reaching effective clobazam dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adults with Epilepsy who have recently been started on Clobazam (Onfi)

Inclusion Criteria:

  • adults aged 18 years or older
  • diagnosis of epilepsy who are being considered for treatment with Clobazam

Exclusion Criteria:

  • known untreated moderate or severe sleep apnea
  • major circadian rhythm disorders

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02911025

Layout table for location information
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Brigham and Women's Faulkner Hospital
Jamaica Plain, Massachusetts, United States, 02130
Sponsors and Collaborators
Brigham and Women's Hospital
Layout table for investigator information
Principal Investigator: Milena Pavlova, MD Brigham and Women's Hospital

Layout table for additonal information
Responsible Party: Pavlova, Milena,M.D., Assistant Professor, Harvard Medical School, Brigham and Women's Hospital Identifier: NCT02911025    
Other Study ID Numbers: 2014P001657
First Posted: September 22, 2016    Key Record Dates
Last Update Posted: January 23, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Pavlova, Milena,M.D., Brigham and Women's Hospital:
antiepileptic drugs
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action